This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Edward A. Mortimer, Jr, MD
Case Western Reserve University School of Medicine Cleveland

JAMA. 1987;258(21):3118-3119.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In Reply.—

In my view, Dr White's letter does not set the record straight. I believe that my editorial remarks are fully documented in the public media and by the "paper trail" left by the Aspirin Foundation of America and several aspirin manufacturers.

Dr White's statement that my editorial is "unfair" to the FDA is inaccurate; I did not criticize the FDA, which never withdrew its 1982 recommendation for a label warning. The FDA was simply overruled by the Office of Management and Budget under pressure from the aspirin industry, as asserted by an Office of Budget and Management staff member (Wall Street Journal, June 6, 1983, pp 1,22).

Dr White takes me to task because various bodies recommended that "better" studies be conducted. Three public advisory bodies recommended that further, not better, studies be undertaken, but all three never changed their opinion that aspirin probably plays an important role . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?